Critical appraisal of lurasidone in the management of schizophrenia

Neuropsychiatric Disease and Treatment, 04/20/2012

Lurasidone did not raise the risk of QTc interval prolongation, although additional studies are required. Long–term trials are also needed to assess the risk of new–onset diabetes. Ongoing trials in patients with bipolar disorder are being completed but, again, efficacy and safety have been investigated only in a few short–term clinical trials.

Print Article Summary Cat 2 CME Report